Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Oberg K ^a   Hellman, P ^a   Ferolla, P ^b   Papotti, M ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Multidisciplinary Group for Diagnosis and Therapy of Neuroendocrine Tumors   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; PLACEBO; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE;

ARTICLE; BRONCHUS TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOID; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FOLLOW UP; HUMAN; INCIDENCE; LARGE CELL NEUROENDOCRINE CARCINOMA; LIVER METASTASIS; LUNG SMALL CELL CANCER; LUNG TUMOR; METASTASIS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; THORAX RADIOGRAPHY; THYMOMA; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHIAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; RISK ASSESSMENT; THYMUS NEOPLASMS;

EID: 84866627212     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds267     Document Type: Article

References (21)

1. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26(18): 3063-3072.
2. Skuladottir H, Hirsch FR, Hansen HH et al. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002; 37(2): 127-135.
3. Gustafsson BI, Kidd M, Chan A et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113(1): 5-21.
4. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 2010; 251(6): 1117-1121.
5. Travis WD. Lung tumors with neuroendocrine differentiation. Eur J Cancer 2009; 45(Suppl. 1): 251-266.
6. Travis WD, Rush W, Flieder DB et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22(8): 934-944.
7. Righi L, Volante M, Rapa I et al. Neuro-endocrine tumors of the lung. A review of relevant pathological and molecular data. Virchows Arch 2007; 451(Suppl. 1): S51-S59.
8. Travis WD, Giroux DJ, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3(11): 1213-1223.
9. Goudet P, Bonithon-Kopp C, Murat A et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. Eur J Endocrinol/Eur Feder Endocr Soc 2011; 165(1): 97-105.
10. Phan AT, Oberg K, Choi J et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010; 39(6): 784-798.
11. Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumors. Clin Endocrinol 2003; 59(6): 793-799.
12. Gabriel M, Decristoforo C, Kendler D et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48(4): 508-518.
13. Rivera MP, Detterbeck F, Mehta AC. Diagnosis of lung cancer: the guidelines. Chest 2003; 123(1 Suppl.): 129S-136S.
14. Lim E, Goldstraw P, Nicholson AG et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2008; 3(10): 1194-1201.
15. Daddi N, Ferolla P, Urbani M et al. Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg 2004; 26(4): 813-817.
16. Lim E, Yap YK, De Stavola BL et al. The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. J Thorac Cardiovasc Surg 2005; 130(4): 969-972.
17. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001; 12(Suppl. 2): S111-S114.
18. Ekeblad S, Sundin A, Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13(10): 2986-2991.
19. Hamada S, Masago K, Mio T et al. Good clinical response to imatinib mesylate in atypical thymic carcinoid with KIT overexpression. J Clin Oncol 2011; 29(1): e9-e10.
20. van Essen M, Krenning EP, Bakker WH et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumors of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34(8): 1219-1227.
21. Warren WH, Gould VE. Long-term follow-up of classical bronchial carcinoid tumors. Clinicopathologic observations. Scand J Thorac Cardiovasc Surg 1990; 24(2): 125-130.